IP Library Granted Patent US 9,399,023
Granted Patent B2
US 9,399,023 · App. 14/734,249 · Granted Jul 26, 2016

Formulation for retinoid-containing soft gelatin capsules

Inventors: Günter Ditzinger (Freiburg, DE); Bernhard Gabriel (Oberuzwil, CH); Anne-Hortense Schmitt-Hoffmann (Basel, CH); Lutz Wevelsiep (Lörrach, DE)
Assignee: Glaxo Group Limited
A61K9/4825A61K9/4858A61K31/07A61K31/203A61K47/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,399,023
App. No.
14/734,249
Granted
Jul 26, 2016
Kind
B2
Abstract

A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.

Claims (34)

1. A pharmaceutical formulation for retinoids comprising a soft gelatin capsule filled with a fill mass comprising 9-cis retinoic acid or a pharmaceutically acceptable salt thereof, a natural vegetable oil, a partially hydrogenated natural vegetable oil, a medium chain triglyceride, and a natural wax, optionally further an antioxidant, and other pharmaceutically acceptable additives,

wherein the fill mass comprises from about 50 to 80% by weight of a natural vegetable oil, and

wherein the fill mass comprises from about 15 to 30% by weight of partially hydrogenated vegetable oil.

2. The pharmaceutical formulation according to claim 1 , wherein the antioxidant is selected from DL-α-tocopherol, butylhydroxy toluene (BHT) and butylhydroxy anisole (BHA).

3. The pharmaceutical formulation according to claim 1 , wherein the natural vegetable oil is selected from soybean oil, corn oil, sunflower oil, rape seed oil, linseed oil, sesame oil, olive oil, coconut oil, peanut oil, safflower oil, castor oil and cottonseed oil or mixtures of two or more of these oils.

4. The pharmaceutical formulation according to claim 3 , wherein the natural vegetable oil is soybean oil.

5. The pharmaceutical formulation according to claim 1 , wherein the partially hydrogenated natural vegetable oil is selected from soybean oil, corn oil, sunflower oil, rape seed oil, linseed oil, sesame oil, olive oil, coconut oil, peanut oil safflower oil, castor oil or cottonseed oil, or mixture of two or more of these oils.

6. The pharmaceutical formulation according to claim 5 wherein the partially hydrogenated natural vegetable oil is soybean oil.

7. The pharmaceutical formulation according to claim 1 , wherein the natural vegetable oil is soybean oil and the partially hydrogenated natural vegetable oil is soybean oil.

8. The pharmaceutical formulation of claim 1 , wherein the fill mass comprises from about 60 to 70% by weight natural vegetable oil.

9. The pharmaceutical formulation according to claim 1 , wherein the natural vegetable oil is soybean oil.

10. The pharmaceutical formulation according to claim 9 , wherein the fill mass comprises from about 20 to 30% by weight of partially hydrogenated vegetable oil.

11. The pharmaceutical formulation according to claim 9 , wherein the partially hydrogenated natural vegetable oil is soybean oil.

12. The pharmaceutical formulation according to claim 1 , wherein the natural wax is yellow wax.

13. The pharmaceutical formulation of claim 1 , wherein the fill mass comprises from about 3 to 6% by weight of natural wax.

14. The pharmaceutical formulation of claim 1 , wherein the fill mass comprises from about 3 to 6% by weight of natural wax and the natural wax is yellow wax.

15. The pharmaceutical formulation according to claim 1 , wherein the capsule has a shell comprising gelatin, one or more plasticizers and water.

16. The pharmaceutical formulation according to claim 15 , wherein the plasticizer is selected from the group consisting of glycerol, sorbitol, propylene glycol, and mixtures of these components.

17. The pharmaceutical formulation according to claim 16 , wherein the plasticizer comprises a mixture of glycerol and sorbitol.

18. The pharmaceutical formulation according to claim 15 , wherein the gelatin is pig gelatin.

19. The pharmaceutical formulation according to claim 15 , wherein the gelatin is bovine gelatin.

20. The pharmaceutical formulation according to claim 1 wherein the triglyceride is a saturated fatty acid containing from 8 to 10 carbon atoms.

21. The pharmaceutical formulation according to claim 20 wherein the triglyceride is a saturated fatty acid containing from 8 to 10 carbon atoms and is selected from caprylic acid, capric acid, or a mixture of caprylic acid and capric acid.

22. The pharmaceutical formulation according to claim 1 , wherein the fill mass comprises from about 1 to 10 percent by weight of the medium chain triglyceride.

23. The pharmaceutical formulation according to claim 20 , wherein the fill mass comprises from about 1 to 10 percent by weight of the medium chain triglyceride.

24. The pharmaceutical formulation according to claim 23 wherein the fill mass comprises from about 6 to 12 percent by weight of the medium chain triglyceride.

25. The pharmaceutical formulation according to claim 2 , wherein the antioxidant is selected from DL-α-tocopherol.

26. The pharmaceutical formulation according to claim 1 , wherein the fill mass comprises from about 50 to 80 percent by weight natural vegetable oil which is soybean oil, and from about 15 to 35 percent by weight of partially hydrogenated vegetable oil which is soybean oil.

27. The pharmaceutical formulation according to claim 26 wherein the triglyceride is a saturated fatty acid containing from 8 to 10 carbon atoms, and from about 3 to 6 percent of the natural wax which is yellow wax.

28. The pharmaceutical formulation according to claim 27 wherein the antioxidant is selected from DL-α-tocopherol, butylhydroxy toluene (BHT) and butylhydroxy anisole (BHA).

29. The pharmaceutical formulation according to claim 28 wherein the capsule has a shell comprising gelatin, one or more plasticizers and water.

30. The pharmaceutical formulation according to claim 29 wherein the gelatin is selected from pig or bovine gelatin.

31. The pharmaceutical formulation according to claim 1 wherein the dermatologically acceptable additives are selected from a colorant, flavoring agent, stabilizer, or emulsifying agent.

32. A method of treatment of a dermatological disease in a patient in need thereof, comprising administering to said patient a pharmaceutical formulation according to claim 1 .

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE U.S. PATENT 9,399,023 IS CORRECTNOT U.S. PATENT 9,339,023 PREVIOUSLY RECORDED ON REEL 054358 FRAME 0326. ASSIGNOR(S) HEREBY CONFIRMS THE BASILEA PHARMACEUTICAINTERNATIONAL LTD (NOV. 1, 2020). Recorded Nov 16, 2020
From: BASILEA PHARMACEUTICA INTERNATIONAL
To: GALEPHAR PHARMACEUTICAL RESEARCH, INC.
Reel/Frame 054421/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2017
From: GLAXO GROUP LIMITED
To: BASILEA PHARMACEUTICA INTERNATIONAL LTD.
Reel/Frame 043414/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2015
From: DITZINGER, GUNTER; GABRIEL, BERNHARD; SCHMITT-HOFFMANN, ANNE-HORTENSE; WEVELSIEP, LUTZ
To: BASILEA PHARMACEUTICA AG
Reel/Frame 035814/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2015
From: BASILEA PHARMACEUTICA INTERNATIONAL LTD.
To: GLAXO GROUP LIMITED
Reel/Frame 035875/0853 →
Priority Claims (1)
EP 03405788 · Nov 3, 2003 · regional
Continuity (3)
Continuation 13086479 · Apr 14, 2011
Continuation 10958704 · Oct 5, 2004
Related Publication 20150265539A1 · Sep 24, 2015